Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) and Theravance, Inc. covers the period ending March 2015, with the report issued on March 19, 2015. The filing details the outcome of a joint US FDA Advisory Committee meeting regarding the supplemental New Drug Application (sNDA) for BREO ELLIPTA (fluticasone furoate/vilanterol) as a once-daily inhaled treatment for asthma in patients aged 12 years and older.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a regulatory update focused on clinical trial outcomes and advisory committee recommendations rather than financial performance.
Material Changes and Regulatory Outcomes
- Adult Approval Recommendation: The FDA Advisory Committee voted in favor of approval for adults (18 years and older) for both 100/25 mcg and 200/25 mcg dose regimens. Votes were 16-4 for efficacy and safety, 18-2 for clinical benefit, and 17-3 for safety demonstration.
- Adolescent Rejection: The Committee voted against approval for the 12-17 year old age group (2 for, 18 against), citing insufficient efficacy data (4 for, 16 against) and inadequate safety demonstration (1 for, 19 against).
- Post-Marketing Requirements: The Committee recommended a large Long-Acting Beta-Agonist (LABA) safety trial for both adults (13 yes, 7 no) and adolescents (17 yes, 2 no) similar to ongoing FDA Post-Marketing Requirements for other LABA manufacturers.
Guidance, Outlook, and Risks
Outlook and Timeline: The FDA is expected to make its final decision on April 30, 2015. Management from both GSK and Theravance stated their commitment to cooperating with the FDA to address outstanding questions and ensure a fully informed decision.
Risks and Contingencies:
- Regulatory Risk: Advisory Committee recommendations are non-binding; the FDA may deviate from the committee's vote.
- Safety Concerns: The filing reiterates the class effect of LABAs increasing the risk of asthma-related death. Breo Ellipta is currently not indicated for asthma in the US.
- Forward-Looking Statements: Both companies caution that actual results may differ materially from projections due to risks including regulatory delays, clinical study outcomes, and collaboration disruptions.
Investor Verification Checklist
- Verify the final FDA decision date (expected April 30, 2015) and whether the agency accepts the Advisory Committee's recommendation for adult approval.
- Confirm the scope and timeline of the recommended large LABA safety trial for adults and its potential impact on commercialization.
- Assess the likelihood of a resubmission or additional data requirements for the 12-17 year old indication given the strong committee vote against approval.
- Review the specific terms of the collaboration agreement between GSK and Theravance regarding royalty revenues for BREO ELLIPTA if approved for asthma.